Compare Strategy Inc. (MSTR) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Tempus AI — how do they compare? Strategy Inc. trades at $155.22 (market cap $61.16B), while Tempus AI trades at $70.5 (market cap $12.77B). The key difference: Strategy Inc. is far larger — about 4.8× Tempus AI's market cap, and Tempus AI is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 112 Days and Tempus AI for 22 Days on average.
| MSTR | TEM | |
|---|---|---|
Market Cap | $61.16B | $12.77B |
Volume | 21,318,561 | 8,980,490 |
Sector | Technology | Broad Market / Factor |
52-Week High | $320.29 | $99.28 |
52-Week Low | $82.31 | $41.55 |
Typical Hold Time | 112 Days | 22 Days |
Enterprise Value | $79.92B | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR stock trades at $151.47, down 7.95% over 24 hours, with a bullish technical signal from moving averages. The company reported a net loss of $3.85 billion for 2025 on revenue of $477.23 million, with a deeply negative net income margin of -6,102.96%. Despite severe profitability challenges, analyst consensus remains optimistic with a $252 price target, and recent news highlights significant stock volatility tied to Bitcoin market movements.
The outlook is bifurcated: strong analyst buy ratings and a high price target suggest upside potential, but fundamental weaknesses including persistent losses and negative cash flow from operations pose substantial risks. Investment appeal hinges on speculative sentiment rather than current financial health, with volatility expected to continue.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
